Published in Lancet on February 24, 1979
Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect Immun (1982) 1.20
Inhibition of Escherichia coli heat-stable enterotoxin by indomethacin and chlorpromazine. Infect Immun (1980) 1.11
Effect of chlorpromazine on the secretory activity of Escherichia coli heat-stable enterotoxin. Infect Immun (1979) 0.98
Lanthanum chloride inhibition of the secretory response to Escherichia coli heat-stable enterotoxin. Infect Immun (1982) 0.89
Jejunal water and electrolyte secretion induced by L-arginine in man. Gut (1981) 0.87
Controlled trial of chlorpromazine as antisecretory agent in patients with cholera hydrated intravenously. Br Med J (Clin Res Ed) (1982) 0.86
Clinical trial of berberine in acute watery diarrhoea. Br Med J (Clin Res Ed) (1985) 0.80
Failure of chlorpromazine to inhibit fluid accumulation caused by Escherichia coli heat-stable enterotoxin in suckling mice. Infect Immun (1981) 0.77
Calcium mediation of the pig jejunal secretory response. Can J Comp Med (1985) 0.77
Nicotinic acid inhibits enterotoxin-induced jejunal secretion in the pig. Can J Comp Med (1981) 0.75
Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid. Infect Immun (1973) 6.58
Enzyme-linked immunosorbent assays for cholera serology. Infect Immun (1973) 6.10
Vibrio cholerae enterotoxin and its mode of action. Bacteriol Rev (1971) 4.98
Actions of cholera toxin and the prevention and treatment of cholera. Nature (1981) 4.78
Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids. Infect Immun (1973) 4.08
Effect of cholera enterotoxin on ion transport across isolated ileal mucosa. J Clin Invest (1972) 3.28
Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology (1986) 3.28
Deactivation of cholera toxin by ganglioside. J Infect Dis (1971) 3.16
Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis (1984) 3.07
Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest (1991) 2.97
Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun (1976) 2.92
Synthesis of a precursor to the B subunit of heat-labile enterotoxin in Escherichia coli. J Bacteriol (1981) 2.84
Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis (1985) 2.78
Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol (1986) 2.77
Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun (1989) 2.74
Antibiotic therapy of cholera. Bull World Health Organ (1967) 2.73
Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. J Clin Microbiol (1986) 2.65
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol (1992) 2.52
Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol (1985) 2.49
Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol. Lancet (1999) 2.47
Interaction of cholera toxin and toxin derivatives with lymphocytes. I. Binding properties and interference with lectin-induced cellular stimulation. J Exp Med (1974) 2.42
Development of improved cholera vaccine based on subunit toxoid. Nature (1977) 2.42
The bactericidal effect of normal human serum on E. coli strains from normals and from patients with urinary tract infections. Infection (1973) 2.39
Effects of prostaglandins, theophylline, and cholera exotoxin upon transmucosal water and electrolyte movement in the canine jejunum. Gastroenterology (1971) 2.39
Experimental studies on cholera immunization. II. Evidence for protective antitoxic immunity mediated by serum antibodies as well as local antibodies. Infect Immun (1972) 2.37
Stimulation of glycerol production in fat cells by cholera toxin. Nature (1970) 2.34
Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci U S A (1975) 2.18
Immunochemical Studies of Two Cholera Toxin-Containing Standard Culture Filtrate Preparations of Vibrio cholerae. Infect Immun (1971) 2.17
Mechanisms of disease and immunity in cholera: a review. J Infect Dis (1977) 2.17
Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13
Correlation between intestinal synthesis of specific immunoglobulin A and protection against experimental cholera in mice. Infect Immun (1978) 2.12
Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of Escherichia coli. Proc Natl Acad Sci U S A (1984) 2.10
Letter: Febrile reactions after methicillin. Lancet (1974) 2.09
Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol (1991) 2.08
Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis (1983) 2.08
Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect Immun (1982) 2.08
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun (1997) 2.05
Cross-reactivity between heat labile enterotoxins of Vibrio cholerae and Escherichia coli in neutralization tests in rabbit ileum and skin. Acta Pathol Microbiol Scand B Microbiol Immunol (1973) 2.04
Public health. The cholera crisis in Africa. Science (2009) 2.02
Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest (1997) 1.98
Identification of a mannose-binding pilus on Vibrio cholerae El Tor. Microb Pathog (1991) 1.94
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
Enterotoxin-producing bacteria and parasites in stools of Ethiopian children with diarrhoeal disease. Arch Dis Child (1976) 1.94
Fixation and inactivation of cholera toxin by GM1 ganglioside. Scand J Infect Dis (1973) 1.90
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lysoGM1 ganglioside. Eur J Biochem (1981) 1.89
Cloning and sequencing of Vibrio cholerae mannose-sensitive haemagglutinin pilin gene: localization of mshA within a cluster of type 4 pilin genes. Mol Microbiol (1994) 1.88
Is Clostridium difficile endemic in chronic-care facilities? Lancet (1986) 1.88
Rice-powder electrolyte solution as oral-therapy in diarrhoea due to Vibrio cholerae and Escherichia coli. Lancet (1982) 1.87
Protective antitoxic cholera immunity in mice: influence of route and number of immunizations and mode of action of protective antibodies. Acta Pathol Microbiol Scand C (1978) 1.86
Monoclonal antibodies to cholera toxin with special reference to cross-reactions with Escherichia coli heat-labile enterotoxin. Infect Immun (1983) 1.84
Conformation of protein secreted across bacterial outer membranes: a study of enterotoxin translocation from Vibrio cholerae. Proc Natl Acad Sci U S A (1987) 1.84
Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand J Immunol (1977) 1.83
Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun (1991) 1.82
Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization. Infect Immun (1975) 1.82
Can vitamin D deficiency produce an unusual pain syndrome? Arch Intern Med (1991) 1.80
Subunit structure of cholera toxin. J Gen Microbiol (1973) 1.78
Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc Natl Acad Sci U S A (1989) 1.74
Development of oral vaccines against enterotoxinogenic Escherichia coli diarrhoea. Vaccine (1989) 1.73
Pathogenesis of Salmonella-mediated intestinal fluid secretion. Activation of adenylate cyclase and inhibition by indomethacin. Gastroenterology (1975) 1.71
Relative significance of mannose-sensitive hemagglutinin and toxin-coregulated pili in colonization of infant mice by Vibrio cholerae El Tor. Infect Immun (1996) 1.70
Evaluation of a ganglioside immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin. J Clin Microbiol (1979) 1.70
Role of PCF8775 antigen and its coli surface subcomponents for colonization, disease, and protective immunogenicity of enterotoxigenic Escherichia coli in rabbits. Infect Immun (1988) 1.69
Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro. Proc Natl Acad Sci U S A (1988) 1.68
Transient entry of enterotoxin subunits into the periplasm occurs during their secretion from Vibrio cholerae. J Bacteriol (1987) 1.68
Rice-based oral rehydration solution decreases the stool volume in acute diarrhoea. Bull World Health Organ (1985) 1.68
Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology (1999) 1.68
Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J Gen Virol (2001) 1.67
Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol (1983) 1.67
Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun (1998) 1.67
Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A (1994) 1.66
Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med (1983) 1.64
Quantitation of vibriocidal antibodies using agar plague techniques. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 1.63
Experimental studies on cholera immunization. 1. The response of neutralizing and vibriocidal antibodies in rabbits after immunization with culture filtrate material from V. cholerae. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.63
Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci (2008) 1.62
Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull World Health Organ (1984) 1.62
Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralising activity and differentiation of human and porcine LTs and cholera toxin. Med Biol (1986) 1.61
Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. Proc Natl Acad Sci U S A (1977) 1.61
Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clin Exp Immunol (2003) 1.60
Antibiotic therapy of cholera in children. Bull World Health Organ (1967) 1.58
Toxins of Vibrio cholerae and Escherichia coli stimulate adenyl cyclase in rat fat cells. Nature (1974) 1.58
Aspergillosis in four renal transplant recipients. Diagnosis and effective treatment with amphotericin B. Ann Intern Med (1972) 1.58
Antisecretory factor suppresses intestinal inflammation and hypersecretion. Gut (1997) 1.57
Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest (1969) 1.56
Cholera in children. Lancet (1966) 1.56
Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine (1993) 1.54
Immunodiffusion studies on Escherichia coli. 1. Identification of O, K and H antigens in an O6 strain. Acta Pathol Microbiol Scand (1969) 1.54
Induction of compartmentalized B-cell responses in human tonsils. Infect Immun (1995) 1.54
Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin. Scand J Immunol (1986) 1.52
Protective capacity of antibodies against E. coli O antigen with special reference to the avidity. Int Arch Allergy Appl Immunol (1974) 1.49
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine (1992) 1.49
Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture. Infect Immun (1989) 1.48
Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera. Infect Immun (1994) 1.46
Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand J Immunol (1987) 1.45